Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

Covid19 Clinical Trial

Official title:

Expanded Access Study of a Single Dose of Exebacase in Addition to Antistaphylococcal Antibiotics for the Treatment of Persistent Methicillin-Resistant Staphylococcus Aureus (MRSA) Bloodstream Infections (Including Right Sided Endocarditis) in Patients Who Are Hospitalized With Coronavirus Disease 2019 (COVID-19)

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT04597242
• Other study ID #: CF-301-107
• Status: No longer available

Study information

• Verified date: September 2021
• Source: ContraFect
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

This is an open-label, expanded access study of exebacase used in addition to antistaphylococcal antibiotics in adult patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI), including right-sided endocarditis (R-IE), who are hospitalized with coronavirus disease 2019 (COVID-19). Patients with left-sided endocarditis (L-IE) are excluded. Patients will receive a single dose of exebacase. Patients will continue to receive antistaphylococcal antibiotics as prescribed by the treating physician. Exebacase Phase 3 study sites (Study CF-301-105) may participate in this Expanded Access study (Study CF-301-107).

Exebacase, a direct lytic agent, is an entirely new treatment modality against S. aureus. Exebacase is a recombinantly-produced, purified cell wall hydrolase enzyme that results in rapid bacteriolysis, potent biofilm eradication, synergy with antibiotics, low propensity for resistance, and the potential to suppress antibiotic resistance when used together with antibiotics. Exebacase represents a first-in-field, first-in-class treatment with the potential to improve clinical outcome when used in addition to standard-of-care antibiotics to treat S. aureus BSI including IE.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female, 18 years of age or older.

• Hospitalized with known COVID-19 infection confirmed by positive diagnostic test.

• Not eligible for the exebacase Phase 3 study (CF-301-105).

• Blood cultures positive for MRSA for =3 days.

• Patient is not pregnant or breastfeeding and is not of reproductive potential or agrees to remain abstinent or use contraception if of reproductive potential.

Exclusion Criteria:

• Known or suspected left-sided IE.

• Intubated for COVID-19.

• Presence of prosthetic valve or cardiac valve support ring, or presence of known infected orthopedic hardware, prosthetic joint, or cardiac device.

• Known or suspected brain abscess or meningitis.

• Participation in an investigational study or expanded access protocol for another antistaphylococcal antibacterial agent.

Related Conditions & MeSH terms

• Bacteremia
• COVID-19
• Covid19
• Endocarditis
• Infections
• MRSA Bacteremia
• MRSA Bloodstream Infection
• MRSA Right-sided Endocarditis
• Sepsis

Intervention

Drug:
• Exebacase
Patients will receive a single IV infusion of exebacase in addition to antistaphylococcal antibiotics prescribed by the treating physician. Patients with normal renal function or mild renal impairment will be administered a dose of 18 mg of exebacase; patients with moderate or severe renal impairment will be administered a dose of 12 mg; patients with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg.

Locations

Country	Name	City	State
United States	CF-301-107 Study Site	Butte	Montana
United States	Cf 301-107	Toledo	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
ContraFect

Country where clinical trial is conducted

United States,